Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

1.

Replicons of a rodent hepatitis C model virus permit selection of highly permissive cells.

Wolfisberg R, Holmbeck K, Nielsen L, Kapoor A, Rice CM, Bukh J, Scheel TKH.

J Virol. 2019 Jul 10. pii: JVI.00733-19. doi: 10.1128/JVI.00733-19. [Epub ahead of print]

PMID:
31292246
2.

Functional Interplay between RNA Viruses and Non-Coding RNA in Mammals.

Damas ND, Fossat N, Scheel TKH.

Noncoding RNA. 2019 Jan 14;5(1). pii: E7. doi: 10.3390/ncrna5010007. Review.

3.

Correction: miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence.

Yu Y, Scheel TKH, Luna JM, Chung H, Nishiuchi E, Scull MA, Echeverría N, Ricardo-Lax I, Kapoor A, Lipkin WI, Divers TJ, Antczak DF, Tennant BC, Rice CM.

PLoS Pathog. 2018 Sep 17;14(9):e1007303. doi: 10.1371/journal.ppat.1007303. eCollection 2018 Sep.

4.

Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.

Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Bukh J.

Gastroenterology. 2018 Apr;154(5):1435-1448. doi: 10.1053/j.gastro.2017.12.015. Epub 2017 Dec 22.

PMID:
29274866
5.

miRNA independent hepacivirus variants suggest a strong evolutionary pressure to maintain miR-122 dependence.

Yu Y, Scheel TKH, Luna JM, Chung H, Nishiuchi E, Scull MA, Echeverría N, Ricardo-Lax I, Kapoor A, Lipkin WI, Divers TJ, Antczak DF, Tennant BC, Rice CM.

PLoS Pathog. 2017 Oct 30;13(10):e1006694. doi: 10.1371/journal.ppat.1006694. eCollection 2017 Oct. Erratum in: PLoS Pathog. 2018 Sep 17;14(9):e1007303.

6.

Viral persistence, liver disease, and host response in a hepatitis C-like virus rat model.

Trivedi S, Murthy S, Sharma H, Hartlage AS, Kumar A, Gadi SV, Simmonds P, Chauhan LV, Scheel TKH, Billerbeck E, Burbelo PD, Rice CM, Lipkin WI, Vandegrift K, Cullen JM, Kapoor A.

Hepatology. 2018 Aug;68(2):435-448. doi: 10.1002/hep.29494. Epub 2018 May 21.

PMID:
28859226
7.

Global mapping of miRNA-target interactions in cattle (Bos taurus).

Scheel TKH, Moore MJ, Luna JM, Nishiuchi E, Fak J, Darnell RB, Rice CM.

Sci Rep. 2017 Aug 15;7(1):8190. doi: 10.1038/s41598-017-07880-8.

8.

Mouse models of acute and chronic hepacivirus infection.

Billerbeck E, Wolfisberg R, Fahnøe U, Xiao JW, Quirk C, Luna JM, Cullen JM, Hartlage AS, Chiriboga L, Ghoshal K, Lipkin WI, Bukh J, Scheel TKH, Kapoor A, Rice CM.

Science. 2017 Jul 14;357(6347):204-208. doi: 10.1126/science.aal1962.

9.

A Broad RNA Virus Survey Reveals Both miRNA Dependence and Functional Sequestration.

Scheel TK, Luna JM, Liniger M, Nishiuchi E, Rozen-Gagnon K, Shlomai A, Auray G, Gerber M, Fak J, Keller I, Bruggmann R, Darnell RB, Ruggli N, Rice CM.

Cell Host Microbe. 2016 Mar 9;19(3):409-23. doi: 10.1016/j.chom.2016.02.007.

10.

miRNA-target chimeras reveal miRNA 3'-end pairing as a major determinant of Argonaute target specificity.

Moore MJ, Scheel TK, Luna JM, Park CY, Fak JJ, Nishiuchi E, Rice CM, Darnell RB.

Nat Commun. 2015 Nov 25;6:8864. doi: 10.1038/ncomms9864.

11.

Hepatitis C virus RNA functionally sequesters miR-122.

Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak JJ, Nishiuchi E, Takacs CN, Catanese MT, de Jong YP, Jacobson IM, Rice CM, Darnell RB.

Cell. 2015 Mar 12;160(6):1099-110. doi: 10.1016/j.cell.2015.02.025.

12.

Characterization of nonprimate hepacivirus and construction of a functional molecular clone.

Scheel TK, Kapoor A, Nishiuchi E, Brock KV, Yu Y, Andrus L, Gu M, Renshaw RW, Dubovi EJ, McDonough SP, Van de Walle GR, Lipkin WI, Divers TJ, Tennant BC, Rice CM.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2192-7. doi: 10.1073/pnas.1500265112. Epub 2015 Feb 2.

13.

Surveying the global virome: identification and characterization of HCV-related animal hepaciviruses.

Scheel TK, Simmonds P, Kapoor A.

Antiviral Res. 2015 Mar;115:83-93. doi: 10.1016/j.antiviral.2014.12.014. Epub 2014 Dec 26. Review.

14.

Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.

Gottwein JM, Jensen SB, Serre SB, Ghanem L, Scheel TK, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J.

Antimicrob Agents Chemother. 2013 Dec;57(12):6034-49. doi: 10.1128/AAC.01176-13. Epub 2013 Sep 23.

15.

Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7.

Galli A, Scheel TK, Prentoe JC, Mikkelsen LS, Gottwein JM, Bukh J.

J Gen Virol. 2013 Oct;94(Pt 10):2221-35. doi: 10.1099/vir.0.053868-0. Epub 2013 Aug 1.

PMID:
23907394
16.

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.

Scheel TK, Rice CM.

Nat Med. 2013 Jul;19(7):837-49. doi: 10.1038/nm.3248. Review.

17.

Identification of a pegivirus (GB virus-like virus) that infects horses.

Kapoor A, Simmonds P, Cullen JM, Scheel TK, Medina JL, Giannitti F, Nishiuchi E, Brock KV, Burbelo PD, Rice CM, Lipkin WI.

J Virol. 2013 Jun;87(12):7185-90. doi: 10.1128/JVI.00324-13. Epub 2013 Apr 17.

18.

Identification of rodent homologs of hepatitis C virus and pegiviruses.

Kapoor A, Simmonds P, Scheel TK, Hjelle B, Cullen JM, Burbelo PD, Chauhan LV, Duraisamy R, Sanchez Leon M, Jain K, Vandegrift KJ, Calisher CH, Rice CM, Lipkin WI.

MBio. 2013 Apr 9;4(2):e00216-13. doi: 10.1128/mBio.00216-13.

19.

Productive homologous and non-homologous recombination of hepatitis C virus in cell culture.

Scheel TK, Galli A, Li YP, Mikkelsen LS, Gottwein JM, Bukh J.

PLoS Pathog. 2013 Mar;9(3):e1003228. doi: 10.1371/journal.ppat.1003228. Epub 2013 Mar 28.

20.

Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.

Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J.

Antimicrob Agents Chemother. 2013 Mar;57(3):1291-303. doi: 10.1128/AAC.02164-12. Epub 2012 Dec 28.

Supplemental Content

Loading ...
Support Center